Fortinet, Inc. (NASDAQ:FTNT) pretends to be active mover, stock shows upbeat performance moved up around 1.81% to traded at $38.24. Fortinet (FTNT) reported the expansion of their threat intelligence and research and development (R&D) operations located in Burnaby, B.C., reinforcing Fortinet’s continued commitment to drive innovation and growth in the Metro Vancouver area.
Fortinet has operated in Burnaby since the year 2000, contributing to economic development and fostering the growth of the technology sector in Canada. The expanded facilities will house 1,000 new technology jobs to staff a state-of-the-art data centre and enhance Fortinet’sFortiGuard Threat Intelligence and R&D centers.
Fortinet’s expanded operations triples their presence in the Metro Vancouver area and more than doubles its presence in Canada. Expanding Fortinet’s Center of Innovation Fortinet’s history in British Columbia dates back to the company’s founding 17 years ago when it opened its first threat intelligence and R&D center in Burnaby. Since then, Fortinet has massively expanded its operations, making Canada its worldwide hub for research and threat intelligence, currently employing nearly 700 people in British Columbia and almost 1000 total employees in Canada.
The expanded campus will enhance Fortinet’s industry-leading FortiGuard threat intelligence capabilities and house a cutting-edge data centre to support the continued growth of its innovative Security Fabric products and services. Located at 4190 and 4260 Still Creek Drive, the campus accommodates 1700 employees and will continue to serve as a R&D hub for the company.
The liquidity measure in recent quarter results of the company was recorded 1.80 as current ratio, on the other side the debt to equity ratio was 0.00, and long-term debt to equity ratio remained 0.00. The Company has gross margin of 73.80% and profit margin was positive 4.70% in trailing twelve months.
Shares of Depomed, Inc. (NASDAQ:DEPO) traded at $6.68 by knocking up of 9.15% in last session.
Levi & Korsinsky, LLP notifies Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017. DEPO The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Depomed engaged in questionable practices in connection with the sales and marketing of the Company’s opioid products; (ii) the foregoing conduct, when it became known, would likely subject the Company to heightened legal and regulatory scrutiny; and (iii) as a result, Depomed’s public statements were materially false and misleading at all relevant times. On August 7, 2017, post-market, Depomed distraded that the Company “received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that the Company had received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.”
Shares price moving up from its 20 days moving average with 8.84% and isolated negatively from 50 days moving average with -21.34%.